NeuroSense (NRSN) gains 12‑month mandate for reverse share split
Rhea-AI Filing Summary
NeuroSense Therapeutics Ltd. (NRSN) reports that shareholders, at a Special Meeting on August 26, 2026, approved authorizing the Board of Directors to implement one or more reverse share splits of the company’s ordinary shares. The Board may select a ratio between 1-for-4 and 1-for-40 and choose an effective date, if any, within 12 months of the meeting. Shareholders also approved that no amendment to the company’s Articles of Association is required in connection with any such reverse share split. The company states that this report is incorporated by reference into several existing Form S-8 and Form F-3 registration statements.
Positive
- None.
Negative
- None.
Key Figures
Authorized reverse split minimum ratio: 1-for-4
Authorized reverse split maximum ratio: 1-for-40
Authorization period: 12 months
+2 more
5 metrics
Authorized reverse split minimum ratio
1-for-4
Minimum aggregate ratio approved for reverse share splits of ordinary shares
Authorized reverse split maximum ratio
1-for-40
Maximum aggregate ratio approved for reverse share splits of ordinary shares
Authorization period
12 months
Board may determine exact ratio and effective date, if any, within 12 months of August 26, 2026
Special Meeting date
August 26, 2026
Date on which shareholders approved the reverse split authorization
Signature date
August 27, 2026
Date the report was signed by Chief Executive Officer Alon Ben-Noon
Key Terms
reverse share split, Articles of Association, incorporated by reference, Form S-8, +1 more
5 terms
Articles of Association regulatory
"no amendment to the Company’s Articles of Association be required"
A company's articles of association are its written rulebook that sets how the business is run, how decisions are made, and what rights owners and directors have—covering voting, meetings, appointment and removal of directors, share classes and dividend policies. For investors, these rules matter because they determine how easily control can change, what protections minority owners have, and how corporate actions (like issuing new shares or changing leadership) are approved, much like a home’s bylaws shaping what residents can and cannot do.
incorporated by reference regulatory
"This Report on Form 6-K is hereby incorporated by reference into"
Form S-8 regulatory
"Registration Statements on Form S-8 (File No. 333-262480 and 333-289658)"
A Form S-8 is a U.S. Securities and Exchange Commission registration that lets a public company set aside shares for employee benefit plans and stock-based compensation. Think of it as opening a dedicated account that authorizes the company to issue or reserve stock for workers and directors; it matters to investors because it enables share dilution when those awards are granted or exercised and signals how management is compensated and incentivized.
Form F-3 regulatory
"and Form F-3 (File No. 333-269306, 333-283656, 333-284051, 333-291122 and 333-293060)"
Form F-3 is a U.S. securities filing that lets eligible foreign companies pre-register and then quickly sell shares or other securities to raise money, because they already meet ongoing reporting and size tests. For investors it signals that the company is up-to-date with regulatory disclosure and has an efficient way to issue new securities — similar to a pre-approved credit line — which can mean faster capital raises but also potential dilution of existing holdings.
FAQ
How does this 6-K relate to NRSN’s existing registration statements?
The report is incorporated by reference into NeuroSense Therapeutics Ltd.’s Form S-8 registration statements (File Nos. 333-262480 and 333-289658) and Form F-3 registration statements (File Nos. 333-269306, 333-283656, 333-284051, 333-291122 and 333-293060).
AI-generated analysis. How Rhea-AI works. Not financial advice.
